 MONT-SAINT-GUIBERT, Belgium--BUSINESS WIRE--Regulatory News: Celyad Oncology SA Brussels:CYAD Paris:CYAD NASDAQ:CYAD Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer the Company, today announced its consolidated financial results for fiscal year 2020 ended December 31, 2020 and provided a business update. The past twelve months have proven to be an evolutiona 